. 2009 Oct 15;12(1):2–6. doi: 10.1093/neuonc/nop002

Table 1.

Correlations between clinical or molecular factors and PFS or OS: univariate analysis. (*: p < 0.05)

	Number of Observations	Median PFS (months)	P-value	Median OS (months)	P-value
Gender
Male	139	41.4	0.59	150.1	0.04*
Female	92	38.9	0.59	192.6	0.04*
Age at diagnosis
<40 years	122	42.6	0.79	Not reached	0.75
>40 years	109	36.8	0.79	163.3	0.75
Preoperative KPS
≤80	28	25.7	0.03*	98.1	0.001*
>80	184	41.4	0.03*	242.6	0.001*
No neurological deficit	129	41.3	0.01*	163.3	0.04*
Neurological deficit	16	19.5	0.01*	98.1	0.04*
No contrast enhancement	179	39.9	0.24	175.8	0.54
Contrast enhancement	36	25.2	0.24	Not reached	0.54
Biopsy/partial resection	134	35.9	0.02*	163.3	0.07
Gross total resection	94	47.3	0.02*	Not reached	0.07
Astrocytoma	43	29.3	0.03*	113.2	0.15
Oligodendroglioma	130	41.4	0.03*	175.8	0.15
Ki-67
≤5%	46	44.5	0.33	Not reached	0.71
>5%	39	35.8	0.33	Not reached	0.71
Postoperative radiotherapy	45	56.8	<0.0001*	163.3	0.7
Delayed radiotherapy	74	23.1	<0.0001*	152.4	0.7
Postoperative chemotherapy	47	35.9	0.52	Not reached	0.46
Delayed chemotherapy	115	35.6	0.52	154.7	0.46
No LOH 1p–19q	149	35.8	0.002*	138.5	<0.0001*
LOH 1p–19q	71	49.5	0.002*	242.6	<0.0001*
No LOH 9p	162	41.4	0.01*	196.2	0.49
LOH 9p	55	31.5	0.01*	150.1	0.49
No LOH 10q	187	42.6	0.03*	192.6	0.1
LOH 10q	30	25.7	0.03*	106.4	0.1